SINGAPORE, Feb. 4, 2026 /PRNewswire/ — This recognition reflects the robust clinical evidence supporting NeuroAiD
II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurological disorders.
Empowered By Evidence (EBE) is an independent, international non-profit organisation, founded in 2014 and based in New York. Its panel of natural health specialists and researchers applies a transparent, science-led process to evaluate natural health products, helping healthcare professionals and their patients make evidence-based decisions. Independent assessors evaluate each product, with no association to the product or its competitors, ensuring objectivity.
Nigel Pollard, Chair of the Board of Directors of EBE, remarked:
“Independent advice, education, and clear product-specific evidence help people make confident, informed choices. Our independent product accreditation is an easy way to find exact products like NeuroAiD
II that can deliver results shown in specific clinical trials.”
EBE helps healthcare professionals and consumers choose natural health products supported by rigorous clinical evidence.
David Picard, CEO of Moleac, commented:
“We are proud to be recognised by the prestigious EBE, a well-respected, independent non-profit. This is a testament to the work we conducted at Moleac over the years—pioneering an innovative approach to develop a complex herbal formulation, supported by a unique standardised proprietary manufacturing process to ensure the consistency and validity of its safety and clinical properties, as documented in over 90 publications.”
For more information on Empowered By Evidence, please visit www.empoweredbyevidence.org
About Moleac
Moleac is a biopharmaceutical company that stays committed to helping patients and their families reconnect with their lives. We address unmet needs of patients suffering a loss of brain function after brain injuries or neurodegenerative diseases. Our focus is to help them regain and maintain independence. We select scientifically proven natural compounds and formulations with origins in traditional medicine, establish their clinical properties, and make them available internationally.
For further information, visit moleac.com
View original content:https://www.prnewswire.com/news-releases/moleac-is-pleased-to-announce-that-neuroaidii-has-been-awarded-gold-accreditation-by-empowered-by-evidence-302679661.html
SOURCE Moleac



BitGo’s move creates further competition in a burgeoning European crypto market that is expected to generate $26 billion revenue this year, according to one estimate. BitGo, a digital asset infrastructure company with more than $100 billion in assets under custody, has received an extension of its license from Germany’s Federal Financial Supervisory Authority (BaFin), enabling it to offer crypto services to European investors. The company said its local subsidiary, BitGo Europe, can now provide custody, staking, transfer, and trading services. Institutional clients will also have access to an over-the-counter (OTC) trading desk and multiple liquidity venues.The extension builds on BitGo’s previous Markets-in-Crypto-Assets (MiCA) license, also issued by BaFIN, and adds trading to the existing custody, transfer and staking services. BitGo acquired its initial MiCA license in May 2025, which allowed it to offer certain services to traditional institutions and crypto native companies in the European Union.Read more